| Literature DB >> 25917636 |
Gabriel Anabwani1, Christoph Königs2, Carlos Giaquinto3, Stella Aslanyan4, John P Sabo4, J-Scott Morrow4, Cornelia Feiterna-Sperling5.
Abstract
In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received ≥48 weeks of treatment with extended-release nevirapine. By last visit, all patients had undetectable viral loads and no new safety signals, demonstrating the safety and efficacy of a once-daily antiretroviral regimen.Entities:
Keywords: HIV-1; extended-release formulation; long-term follow-up; nevirapine; pediatric patients
Mesh：
Substances：
Year: 2015 PMID： 25917636 DOI： 10.1093/cid/civ340
Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079